Joseph Alvarnas, MD, vice president of government affairs, City of Hope, and chief clinical advisor, AccessHope, Duarte, California, discusses potential payer biases against experimental or investigational clinical trials and the payer’s role in trial diversity.
Alvarnas served as cochair for the 11th Annual Patient-Centered Oncology Care® (PCOC) meeting, presented by The American Journal of Managed Care® November 9-10, 2022, in Nashville, Tennessee. He spoke with Evidence-Based Oncology™ (EBO) about a panel discussion he chaired on improving diversity in clinical trials.
EBO: What are some common payer barriers for participating in clinical trials?
Alvarnas: Some of the challenges historically have been related to this idea of something being experimental or investigational. The idea that you should pay for care that is an established standard or that represents best practice is something that both payers and clinicians have embraced. What makes cancer care different is that, for a significant percentage of patients that we serve, optimal care has yet to be identified—or we have therapies that may work very well, but [with associated] toxicities are not what we would want.
I think context is really important, and if we can engage payers in a discussion as to the value of a clinical trial—a well-designed, very appropriately constructed clinical trial that can actually answer specific clinical questions and potentially deliver value to patients—then I think we can reset this idea that experimental and investigational represents some irresponsible practice of medicine. For many patients in the cancer care domain, it represents the top choice for best practice.
EBO: Why do payers have a stake in greater diversity in clinical trials?
Alvarnas: [W]e’re living in a nation that’s becoming increasingly diverse, and there are 2 challenges in that increasing diversity. The first is we want to make sure that our health care system is appropriately patient-centered, and if you can’t respect or integrate that level of emerging and growing diversity into how we deliver care, then you’ve already created a system that’s not very good at delivering care to diverse populations or to the nation as a whole.
The other aspect of this is we don’t know what we don’t know. The beauty of clinical trials is we can identify new knowledge and new knowledge that’s hopefully applicable to either an entire population or to subsets within that population. In the realm of knowing to what extent clinical trial findings are generalizable, we have to diversify who’s enrolled in that trial, because we’re not all biologically identical, and not all people are superimposable. So, if we can better understand the applicability of a clinical trial and the generalizability of those results, then it helps us to empower better decision-making after that trial is complete.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen